Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Roche Holding AGXSWX:RO +5.15%75 Shiller PE Ratio is 24.24 as of Jul. 24, 2026, which is 4% above its 10-year median of 23.21. GuruFocus rates XSWX:RO with a GF Score™ of 75/100 and a GF Value™ of CHF268.89 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 537 Drug Manufacturers companies, Roche Holding AG ranks better than 53.82% on this metric.
As of today (2026-07-24), Roche Holding AG's current share price is CHF355.40. Roche Holding AG's E10 for the fiscal year that ended in Dec25 was CHF14.66. Roche Holding AG's Shiller PE Ratio for today is 24.24.
The historical rank and industry rank for Roche Holding AG's Shiller PE Ratio or its related term are showing as below:
XSWX:RO'
s Shiller PE Ratio Range Over the Past 10 Years
Min: 15.66 Med: 23.21 Max: 31.26
Current: 23.29
During the past 13 years, Roche Holding AG's highest Shiller PE Ratio was 31.26. The lowest was 15.66. And the median was 23.21.
XSWX:RO's Shiller PE Ratio is ranked better than 53.82% of 537
companies
in the Drug Manufacturers industry
Industry Median: 24.8
vs XSWX:RO: 23.29
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.
Roche Holding AG's adjusted earnings per share data of for the fiscal year that ended in Dec25 was CHF16.040. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is CHF14.66 for the trailing ten years ended in Dec25.
Shiller PE for Stocks: The True Measure of Stock Valuation
Roche Holding AG (XSWX:RO) Shiller PE Ratio Explanation
Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.
Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.
Be Aware
Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.
Roche Holding AG Shiller PE Ratio Related Terms
Roche Holding AG Shiller PE Ratio Historical Data
* Premium members only.
The historical data trend for Roche Holding AG's Shiller PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:RO vs LLY, JNJ, ABBV: Shiller PE Ratio Comparison
For the Drug Manufacturers - General subindustry, Roche Holding AG's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Roche Holding AG Shiller PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Roche Holding AG's Shiller PE Ratio distribution charts can be found below:
* The bar in red indicates where Roche Holding AG's Shiller PE Ratio falls into.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Roche Holding AG's E10 for the fiscal year that ended in Dec25 is calculated as:
For example, Roche Holding AG's adjusted earnings per share data for the fiscal year that ended in Dec25 was:
Add all the adjusted EPS together and divide 10 will get our E10.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Roche Holding AG (XSWX:RO) has a Shiller PE Ratio of 24.24 as of Jul. 24, 2026. Shiller price-earnings ratio is the ratio of share price to a company's inflation-adjusted earnings over a 10-year period. View historical data on Roche Holding AG and its competitors. This is near median its historical median of 23.21. Over the past decade, Roche Holding AG's Shiller PE Ratio has ranged from 15.66 to 31.26. According to the industry distribution chart, Roche Holding AG ranks #248 out of 537 companies in the Drug Manufacturers industry, placing it in the top 46.2%.
Is Roche Holding AG's Shiller PE Ratio too high?
Roche Holding AG's current Shiller PE Ratio of 24.24 is near median its 10-year median of 23.21. Over the past 10 years, this metric has ranged from a low of 15.66 to a high of 31.26. The Drug Manufacturers industry median Shiller PE Ratio is 24.80. Roche Holding AG's value of 24.24 is 2.3% below this industry median. Based on the distribution chart, Roche Holding AG ranks #248 out of 537 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Roche Holding AG has a GF Score™ of 75/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Roche Holding AG's Shiller PE Ratio compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Roche Holding AG ranks #248 out of 537 companies for Shiller PE Ratio. This puts Roche Holding AG in the upper half of its industry. The industry median Shiller PE Ratio is 24.80. Roche Holding AG's value of 24.24 is 2.3% below this benchmark. Historically, Roche Holding AG's own Shiller PE Ratio has ranged from 15.66 to 31.26 over the past decade. While the company's 10-year median is 23.21 vs. the industry median of 24.80, Roche Holding AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shiller PE Ratio for a Drug Manufacturers company?
The median Shiller PE Ratio among Drug Manufacturers companies is 24.80, based on 537 companies in the industry. Companies in the top quartile (top 25%) have a Shiller PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Shiller PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Roche Holding AG's current Shiller PE Ratio of 24.24 is 2.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shiller PE Ratio mean?
A high Shiller PE Ratio can signal that a stock is expensive relative to its fundamentals. Shiller price-earnings ratio is the ratio of share price to a company's inflation-adjusted earnings over a 10-year period. View historical data on Roche Holding AG and its competitors. For the Drug Manufacturers industry, the median Shiller PE Ratio is 24.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Roche Holding AG's current Shiller PE Ratio is 24.24, which is near median its own 10-year median of 23.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Roche Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Roche Holding AG (XSWX:RO) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF268.89, compared to a current price of CHF355.40 — trading 32.2% above its estimated fair value. The current Shiller PE Ratio is 24.24, which is near median its 10-year median of 23.21 and 2.3% below the Drug Manufacturers industry median of 24.80. Roche Holding AG's overall GF Score™ is 75/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shiller PE Ratio calculated?
Shiller PE Ratio is calculated from a company's financial statements. For Roche Holding AG (XSWX:RO), the current Shiller PE Ratio is 24.24 as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Roche Holding AG (XSWX:RO) Overvalued in 2026?
Based on GuruFocus' analysis, Roche Holding AG stock appears to be overvalued.
The current stock price of CHF355.40 is trading 32.2% above its estimated GF Value™ of CHF268.89.
GuruFocus considers Roche Holding AG to be Significantly Overvalued.
Key valuation signals for XSWX:RO:
Shiller PE Ratio: 24.24 (near median its 10-year median of 23.21)
GF Value™: CHF268.89 vs. price of CHF355.40 (32.2% above fair value)
Industry Position: 2.3% below the Drug Manufacturers median (#248 of 537)
No single metric tells the full story. See the XSWX:RO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 40% of pharmaceutical sales, and centralized and point-of-care diagnostics for two-thirds of diagnostic-related sales.
75GF Score
Get the complete analysis for XSWX:RO
Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:RO has been successfully added to your 
